Bradley Foster & Sargent Inc. CT Trims Stake in Solventum Co. (NYSE:SOLV)

Bradley Foster & Sargent Inc. CT cut its position in Solventum Co. (NYSE:SOLV) by 7.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,764 shares of the company’s stock after selling 549 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Solventum were worth $447,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Foundations Investment Advisors LLC acquired a new stake in shares of Solventum in the third quarter valued at approximately $345,000. Sequoia Financial Advisors LLC boosted its stake in shares of Solventum by 8.3% during the third quarter. Sequoia Financial Advisors LLC now owns 5,737 shares of the company’s stock worth $400,000 after buying an additional 441 shares during the period. Eastern Bank purchased a new position in shares of Solventum during the third quarter worth about $105,000. International Assets Investment Management LLC grew its holdings in shares of Solventum by 5,118.4% during the third quarter. International Assets Investment Management LLC now owns 129,261 shares of the company’s stock worth $9,012,000 after buying an additional 126,784 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its position in Solventum by 4,765.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 319,628 shares of the company’s stock valued at $22,284,000 after acquiring an additional 313,058 shares during the period.

Solventum Stock Performance

Shares of NYSE SOLV opened at $73.08 on Friday. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $96.05. The firm has a 50-day moving average price of $71.14 and a 200 day moving average price of $69.15. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Analyst Ratings Changes

SOLV has been the subject of a number of recent research reports. Piper Sandler increased their price objective on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Mizuho began coverage on shares of Solventum in a research note on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price target on the stock. Finally, Morgan Stanley increased their price target on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $68.29.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.